Device Trial Radar · NCT05765266
ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
May 13, 2024
Primary completion
Jul 15, 2025
Study completion Feb 9, 2026
Sponsor
- Lead sponsor
- Arthrex, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 13, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, multicenter (up to 4 sites), randomized, double-blind, two-arm study. Forty-five (45) patients will be randomized to receive a single 4-6 ml intra-articular (IA) injection of either the output of ACP Max™ (n=30) or 6 ml of Depo-Medrol® (methylprednisolone acetate) (n=15).
Conditions
- Knee Osteoarthritis
Interventions
ACP Max™Device
Single 4-6 ml intra-articular (IA) injection of the output of ACP Max™
Depo-Medrol®Device
Single IA injection of 40 mg of methylprednisolone acetate (1 ml of solution) mixed with 5 ml of Normal Saline for a total of 6 ml.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 6 months
- Adverse EventsTime frame: 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The Center for Clinical Research
Winston-Salem, North Carolina
AMR Knoxville
Knoxville, Tennessee
Spectrum Medical, Inc.
Danville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.